Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies

Autor: D. Thomalla, L. Beckmann, C. Grimm, M. Oliverio, L. Meder, C. D. Herling, P. Nieper, T. Feldmann, O. Merkel, E. Lorsy, A. da Palma Guerreiro, J. von Jan, I. Kisis, E. Wasserburger, J. Claasen, E. Faitschuk-Meyer, J. Altmüller, P. Nürnberg, T.-P. Yang, M. Lienhard, R. Herwig, K.-A. Kreuzer, C. P. Pallasch, R. Büttner, S. C. Schäfer, J. Hartley, H. Abken, M. Peifer, H. Kashkar, G. Knittel, B. Eichhorst, R. T. Ullrich, M. Herling, H. C. Reinhardt, M. Hallek, M. R. Schweiger, L. P. Frenzel

Publikováno v: Blood

The BCL2 inhibitor venetoclax has been approved to treat different hematological malignancies. Because there is no common genetic alteration causing resistance to venetoclax in chronic lymphocytic leukemia (CLL) and B-cell lymphoma, we asked if epige

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fd9e62eaac98abbf92d44c6b7bbeddd
https://doi.org/10.1182/blood.2021014304

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

Autor: Daniel Rauh, Lukas C. Heukamp, Ingelore Baessmann, Silvia Querings, Roland T. Ullrich, C. Ligorio, Egbert F. Smit, Jonathan Weiss, Ines Dabow, Patrick Wagener, Jakob Schöttle, Stefania Damiani, Hannie Sietsma, Roopika Menon, Philippe Lorimier, Martin Peifer, Holger Moch, Thomas Zander, Roman K. Thomas, Walburga Engel-Riedel, Jörg Sänger, Franziska Gabler, Matthias Baumann, Steinar Sollberg, Hyatt Balke-Want, Matthew Conron, Peter Nürnberg, Stefanie Heynck, Christian Brambilla, Erich Stoelben, Zoe Wainer, Janine Altmüller, Rameen Beroukhim, Florian Fischer, Joachim H. Clement, Karen Ernestus, Iver Petersen, Federico Cappuzzo, Erik Thunnissen, Sascha Ansén, William Pao, Jürgen Wolf, Martin L. Sos, Mirjam Koker, Elisabeth Brambilla, Prudence A. Russell, Ben Solomon, Michael Hallek, Sebastian Maier, Alex Soltermann, Johannes M. Heuckmann, Harry J.M. Groen, Daniëlle A.M. Heideman, Reinhard Buettner, Gavin M. Wright, Corinna Ludwig, Sven Perner, Bert Klebl, Odd Terje Brustugun, Wim Timens, Frauke Leenders, Danila Seidel

Publikováno v: Weiss, J, Sos, M L, Seidel, D, Peifer, M, Zander, T, Heuckmann, J M, Ullrich, R M, Menon, R, Maier, S, Soltermann, A, Moch, H, Thunnissen, F B J M, Smit, E F, Heideman, D A M, Perner, S & Thomas, R K 2010, ' Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer ', Science Translational Medicine, vol. 2, no. 62, pp. 62-93 . https://doi.org/10.1126/scitranslmed.3001451
Science Translational Medicine, 2(62):ARTN 62ra93. AMER ASSOC ADVANCEMENT SCIENCE
Science Translational Medicine, 2(62), 62-93. American Association for the Advancement of Science

Lung cancer remains one of the leading causes of cancer-related death in developed countries. Although lung adenocarcinomas with EGFR mutations or EML4-ALK fusions respond to treatment by epidermal growth factor receptor (EGFR) and anaplastic lymphom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b736b3505d1eceaf9c4e0acbe5e40ca
https://research.vumc.nl/en/publications/7c7ef946-d40a-4be9-a092-688601520bd2